OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation

References

• Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationship to age, gender and ethnicity. Cephalalgia. 2003;23(7):519–527.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International headache Society (IHS). Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Manack AN, Buse DC, Lipton R. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–78.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. Clinical guideline [CG150], 2015, [cited 2021 Mar 15]. Available from: https://www.nice.org.uk/guidance/cg150.
   Google Scholar
• British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache and medication-overuse headache. 2019. [cited 2021 Mar 17]. Available from: http://www.bash.org.uk.
   Google Scholar
• Schulman EA, Brahin EJ. Refractory headache: historical perspective, need, and purposes for an operational definition. Headache. 2008;48(6):770–777.
   PubMed Web of Science ®Google Scholar
• D’Antona L, Matharu M. Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain. 2019;20(1):89.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Veron SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Technical appraisal guidance [TA260]. 2012). [cited 2021 Mar 17]. Available from: https://www.nice.org.uk/guidance/ta260.
   Google Scholar
• Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum Neurotoxins: biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200–235.
   PubMed Web of Science ®Google Scholar
• Dressler D. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761–1768.
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):592–596.
   PubMed Web of Science ®Google Scholar
• Peng L, Liu H, Ruan H, et al. Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival. Nat Commun. 2013;4(1):1472.
   PubMedGoogle Scholar
• Barnes M. Botulinum toxin- mechanisms of action and clinical use in spasticity. J Rehabil Med. 2003;35:56–59.
   Web of Science ®Google Scholar
• Han J, Pluhackova K, Boeckmann RA. The multifaceted role of SNARE proteins in membrane fusion. Frontier Physiol. 2017;8:5.
   PubMed Web of Science ®Google Scholar
• Simpson LL. I DENTIFICATION OF THE MAJORSTEPS IN BOTULINUM TOXINACTION. Ann Rev Pharmacol Toxicol. 2004;44(1):167–193.
   PubMedGoogle Scholar
• Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044–1049.
   PubMed Web of Science ®Google Scholar
• Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–350.
   PubMedGoogle Scholar
• Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;328(8501):245–247.
   Google Scholar
• Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2(4):237–254.
   PubMed Web of Science ®Google Scholar
• Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669–676.
   PubMed Web of Science ®Google Scholar
• Moulton EA, Burstein R, Tully S, et al. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One. 2008;3(11):e3799.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Phase-by-phase A. Review of migraine pathophysiology. Headache. 2018;58(Suppl. 1):4–16.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34(11):853–869.
   PubMed Web of Science ®Google Scholar
• Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42.
   PubMed Web of Science ®Google Scholar
• Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon. 2000;38(2):245–258.
   PubMed Web of Science ®Google Scholar
• Burstein R, Blumenfeld AM, Silberstein SD, et al. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60(7):1259–1272.
   PubMed Web of Science ®Google Scholar
• Bomba-Warczak E, Vevea JD, Brittain JM, et al. Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurones. Cell Rep. 2016;16(7):1974–1987.
   PubMed Web of Science ®Google Scholar
• Cai BB, Francis J, Brin MF, et al. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurones and localized on the plasma membrane following intramuscular toxin injection. Neuroscience. 2017;352:155–169.
   PubMed Web of Science ®Google Scholar
• Weise D, Weise CM, Naumann M. Central effects of botulinum neurotoxin- evidence from human studies. Toxins (Basel). 2019;11(1):21.
   Google Scholar
• Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120(2):275–290.
   PubMed Web of Science ®Google Scholar
• Ghosal KJ, Patel K, Singh BR, et al. Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers. PLoS One. 2018;13(7):e0199524.
   PubMed Web of Science ®Google Scholar
• Keller JE, Neale EA, Oyler G, et al. Persistence of botulinum neurotoxin action in cultured spinal cord cells1,2. FEBS Lett. 1999;456(1):137–142.
   PubMed Web of Science ®Google Scholar
• De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. PNAS. 1999;96(6):3200–3205.
   PubMed Web of Science ®Google Scholar
• Wein T, Esquenazi A, Jost WH, et al. OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized trial. PM&R. 2018;10(7):693–703.
   Web of Science ®Google Scholar
• Rogozhin AA, Pang KK, Bukharaeva E, et al. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol. 2008;586(13):3163–3182.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Kotiya A, Kiris E, et al. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA. 2017;114(26):E5158– 5166.
   PubMed Web of Science ®Google Scholar
• Rossotto O. The binding of botulinum neurotoxins to different peripheral neurons. Toxicon. 2018;147:27–31.
   PubMed Web of Science ®Google Scholar
• Elkind AH, O’Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type a for migraine prophylaxis. J Pain. 2006;7(10):688–696.
   PubMed Web of Science ®Google Scholar
• Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001;41(7):658–664.
   PubMed Web of Science ®Google Scholar
• Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. 2000;40(4):300–305.
   PubMed Web of Science ®Google Scholar
• Rollnik JD, Karst M, Fink M, et al. Botulinum toxin A and EMG: a key to the understanding of chronic tension-type headaches? Headache. 2001;41(10):985–989.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Göbel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel0group study. Cephalalgia. 2006;26(7):790–800.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Frishberg BM, Gawel M, et al. BOTOX CDH study group botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293–307.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Stark SR, Lucas SM, et al. BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80(9):1126–1137.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analysis of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–1373.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Diener H-C, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61–70.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001.
   PubMed Web of Science ®Google Scholar
• Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015;156(12):2616–2626.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Aurora SK, Laranjo K, et al. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15(1):100.
   PubMedGoogle Scholar
• Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.
   PubMedGoogle Scholar
• Blumenfeld AM, Stark R, Adams AM, et al. Efficacy and safety of onabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL. Cephalalgia. 2016;36(Suppl. 1):27–28.
   Google Scholar
• Blumenfeld AM, Tepper S, Robbins LD, et al. The effects of onabotulinumtoxinA treatment on the chronic migraine comorbidities of sleep and fatigue. Neurology. 2018;90(15 Supplement):4.131.
   Google Scholar
• Blumenfeld AM, Tepper S, Robbins LD, et al. Effects of onabotulinumtoxinA treatment on the chronic migraine comorbidities of depression and anxiety: psychiatric comorbidties responder analysis. Neurology. 2018;90(15 Supplement):4.126.
   Google Scholar
• Aurora S, Stark RJ, Reppine A, et al. Descriptive comparison of the efficacy and safety of onabotulinumtoxinA for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: COMPEL vs PREEMPT. Headache. 2015;55(Suppl. 3):142.
   Google Scholar
• Ahmed F, Gaul C, Garcia-Monco JC, et al. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):26.
   PubMedGoogle Scholar
• Khalil M, Zafar HW, Quarshie V, et al. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15(1):54.
   PubMedGoogle Scholar
• Ahmed F, Buture A, Tanvir T, et al. Long term outcome for onabotulinumtoxinA (Botox) therapy in chronic migraine: a 2-year prospective follow-up audit of patients attending the Hull (UK) migraine clinic. Cephalalgia Rep. 2021;4:1–9.
   Google Scholar
• Andreou AP, Trimboli M, Al-Kaisy A, et al. Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-national institute for health and care excellence UK technology appraisal. Eur J Neurol. 2018;25(8):1069–e83.
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. SpringerPlus. 2015;4(1):826.
   PubMedGoogle Scholar
• Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17(1):1.
   PubMedGoogle Scholar
• Dominguez C, Pozo-Rosich P, Torres-Ferrus M, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018;25(2):411–416.
   PubMed Web of Science ®Google Scholar
• Ahmed F, Buture A, Tanvir T, et al. Hull Prospective Analysis of OnabotulinumtoxinA (Botox) in the treatment of Chronic Migraine; a real-life data in 972 patients; updated results on over 8 years of experience [abstract no. IHC-PO-423]. Cephalalgia. 2019;39(1 Suppl):276–277.
   Google Scholar
• Ahmed F, Zafar HW, Buture A, et al. Does analgesic overuse matter? Response to onabotulinumtoxinA in patients with chronic migraine with or without medication overuse. SpringerPlus. 2015;4(1):589.
   PubMedGoogle Scholar
• Diener H-C, Dodick DW, Turkel CC, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851–859.
   PubMed Web of Science ®Google Scholar
• Matharu M, Pascual J, Remahl IN, et al. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017;37(14):1384–1397.
   PubMed Web of Science ®Google Scholar
• Winner PK, Blumenfeld AM, Eross EJ, et al. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: results of the COMPEL Study. Drug Saf. 2019;42(8):1013–1024.
   PubMed Web of Science ®Google Scholar
• Botulinum toxin type A (Botox) package insert. 2013, [cited 2021 Mar 25]. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf.
   Google Scholar
• Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. Mil Med. 2014;179(6):e703–4.
   PubMedGoogle Scholar
• Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf. 2016;25(2):179–187.
   PubMed Web of Science ®Google Scholar
• Wong HT, Khalil M, Ahmed F. OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain. 2020;21(1):129.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Schim JD, Chippendale TJ, et al. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48(2):210–220.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–823.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–180.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxina (BOTOX®) and Topiramate (TOPAMAX ®) for the prophylactic treatment of chronic migraine: a Pilot Study. Headache. 2009;49(10):1466–1478.
   PubMed Web of Science ®Google Scholar
• Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21–32.
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59(10):1700–1713.
   PubMed Web of Science ®Google Scholar
• Herd CP, Tomlinson CL, Rick C, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value: final evidence report. [cited 2021 Mar 25]. Available from: ICER_Migraine_Final_Evidence_Report_070318.pdf (nih.gov)
   Google Scholar
• She T, Chen Y, Tang T, et al. Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis. Medicine (Baltimore). 2020;99(5):e18929.
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):1–10.
   PubMedGoogle Scholar
• Am A, Ml R, Km F, et al. Exploring the boundaries between episodic and chronic migraine: results from the CaMEO Study. Headache. 2020;60(S1 suppl):1–156.
   PubMedGoogle Scholar
• Zafar H, Khalil M, Ahmed F, et al. OnabotulinumtoxinA (Botox) in the prevention of chronic migraine: comparing NICE criteria versus Hull criteria for evaluating responder rates. J Headache and Pain. 2014;15(Suppl S1):G2.
   PubMedGoogle Scholar
• Talbot J, Stuckey R, Crawford L, et al. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes. J Headache Pain. 2021;22(1):5.
   PubMed Web of Science ®Google Scholar
• Cohen F, Armand C, Lipton RB, et al. Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021; published online ahead of print March 8, 2021. https://doi.org/10.1093/pm/pnab093].
   Google Scholar
• Blumenfeld AM, Frishberg BM, Schim JD, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021; [published online ahead of print April 21, 2021. https://doi.org/10.1007/s40122-021-00264-x.
   Google Scholar
• Boudreau GP. Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 2020;4(1):1–4.
   Google Scholar